Epiomic Epidemiology Series: Age-Related Macular Degeneration Forecast in 7 Major Markets 2016-2026

Friday, April 29, 2016 General News J E 4

NEW YORK, April 28, 2016 /PRNewswire/ -- Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Age-related Macular Degeneration (AMD) Disease in 7 Major MarketsAge-related macular degeneration (AMD or ARMD) or Age-related Maculopathy (ARM) is a condition that involves the degeneration and damage to the central area of the retina – the macula. It is currently a common cause of visual impairment in Western Europe. AMD is typically painless, and the loss of central vision usually occurs in both eyes but may progress at different speeds.This report provides the current prevalent population for AMD across 7 Major Markets (USA, France, Germany, Italy, Spain, UK and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of AMD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.Main symptoms and co-morbidities for AMD include:-Serous retinal detachment-Haemorrhage-Charles Bonnet Syndrome -Depression-Reduced quality of life-Hypertension-Hypercholesterolaemia (abdominal obesity is a specific risk factor for males)This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report. Reason to buy-Able to quantify patient populations in global AMD's market to target the development of future products, pricing strategies and launch plans. -Gain further insight into the prevalence of the subdivided types of AMD and identify patient segments with high potential.-Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.-Provide a level of understanding on the impact from specific co-morbid conditions on AMD's prevalent population.-Identify sub-populations within AMD which require treatment.-Gain an understanding of the specific markets that have the largest number of AMD patients.Read the full report: Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________Contact Clare: US: (339)-368-6001Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:

SOURCE Reportlinker



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Arbro Launches Nanotechnology Based Bioavailable C...
Epiomic Epidemiology Series: Chronic Kidney Diseas...